All In Biotech

NDA 021336 · Somerset

Emsam

Selegiline · Transdermal · Monoamine Oxidase Inhibitor; Monoamine Oxidase Type B Inhibitor

Last checked: Nov 20, 2026Latest source record: Jul 14, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Feb 27, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

34

3 Phase 3, 0 recruiting

FAERS reports

2,999

1,411 serious, 174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . EMSAM is contraindicated in patients less than 12 years of age because of an increased risk of hypertensive crisis [see Contraindications (4) and Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). • EMSAM is...

What it is approved for

From the label in effect May 15, 2020.

EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . EMSAM ® (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) ( 1 ).

Mechanism: The mechanism of action of selegiline (the drug substance of EMSAM) as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • EMSAM · SELEGILINE 9MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • EMSAM · SELEGILINE 12MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • EMSAM · SELEGILINE 6MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Selegiline" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective329
  • insomnia189
  • application site erythema183
  • hallucination171
  • dizziness170
  • fall147
  • dyskinesia140
  • drug interaction135
  • anxiety128
  • depression128
  • application site rash127
  • tremor121

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
200635
2007311
200827
200943
201034
2011203
2012182
2013145
201451
2015199
2016194
2017224
2018174
2019195
2020193
2021165
2022129
2023147
2024112
2025132
2026100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Emsam (Selegiline)

2024 spending

$12.5M

Beneficiaries

866

5,355 claims

Per beneficiary

$14,487

$71.43 per unit

View as table
YearSpending
2020$11,786,120
2021$12,367,030
2022$11,918,838
2023$12,397,890
2024$12,546,115

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 290 on PubMed

Sponsor: Somerset

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.